EUVIMEDEUVIMED entdecken
Multizentrische Studie

Effect of TKI Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation on Recurrence of Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia p190 and p210 Transcripts: A Multicentre Study

Jiayi Zhen, Shuping Lai, Xiangzhong Zhang, Lijun Huang, Ping Li, Yue Lin, Duorong Xu, Ganlin He

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2024.12.014 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Jiayi Zhen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors, Neoplasm Recurrence, Local. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To analyze the impact of tyrosine kinase inhibitor (TKI) maintenance therapy following allogeneic hematopoietic stem cell transplantation (HSCT) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) on recurrence rates and prognosis for the 2 transcripts, p190 and p210. METHODS: We conducted a retrospective analysis of clinical data from 58 patients diagnosed with Ph + ALL who underwent HSCT. All patients received TKI maintenance therapy following hematopoietic reconstruction post-transplantation. We compared the clinical characteristics and prognostic differences between 2 transcript types: p190 (n = 43) and p210 (n = 15). RESULT: In terms of clinical characteristics, no significant differences were observed between patients with the 2 transcripts. Multivariate analysis revealed that the T3151 mutation (HR = 5.021, 95% CI [1.129-22.3], P = .034) was an independent risk factor for relapse-free survival (RFS) post-transplantation. Additionally, TKI maintenance therapy for over 1 year was identified as a protective factor for RFS (HR = 0.315, 95% CI [0.115-0.86], P = .025). The median RFS was 89.4 months for the p190 group compared to 59.1 months for the p210 group, which was statistically significant (P = .031). In the subgroup with more than 1 year of TKI maintenance therapy, the median RFS times for p190 and p210 were 95.3 and 90.5 months, respectively, with no statistically significant difference in RFS (P = .080). CONCLUSION: The p190 group demonstrated longer RFS compared to the p210 group. However, with early HSCT following induction remission and long-term TKI maintenance therapy post-transplant, the poor prognosis associated with p210 could be mitigated, leading to a trend towards equivalence in outcomes between the 2 transcripts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsNeoplasm Recurrence, LocalHumansMaleFemaleAdultMiddle AgedRetrospective StudiesAdolescentYoung AdultTransplantation, HomologousPhiladelphia ChromosomePrognosisRecurrence

Stichwörter der Autor:innen

BCR::ABL1Ph + ALLRelapse-free survivalTranscript typesTyrosine kinase inhibitors

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Haematology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Department of Hematology, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
  • Department of Hematology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Department of Haematology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Electronic address: Duorong1014@126.com.
  • Department of Haematology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Electronic address: louise.henry@126.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhen, J., Lai, S., Zhang, X., Huang, L., Li, P., Lin, Y., Xu, D., & He, G. (2025). Effect of TKI Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation on Recurrence of Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia p190 and p210 Transcripts: A Multicentre Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.12.014

Vancouver

Zhen J, Lai S, Zhang X, Huang L, Li P, Lin Y, et al. Effect of TKI Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation on Recurrence of Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia p190 and p210 Transcripts: A Multicentre Study. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2024.12.014

BibTeX
@article{Zhen2025,
  author = {Zhen, Jiayi and Lai, Shuping and Zhang, Xiangzhong and Huang, Lijun and Li, Ping and Lin, Yue and Xu, Duorong and He, Ganlin},
  title = {Effect of TKI Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation on Recurrence of Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia p190 and p210 Transcripts: A Multicentre Study},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2024.12.014}
}
Kostenlos starten →